Company intelligence / Profile preview

Inimex Pharmaceuticals

Vancouver, British Columbia, Canada

Ownership: Private
Employees: ~10
Development stage: Other

Overview

IMX942, an Innate Defense Regulator peptide, demonstrated safety in Phase 1 and reduction of oral and gut mucositis severity and duration in preclinical models; Phase 2 studies were planned for infection and mucositis in cancer and high-risk hospitalized patients[4][6][8].

Therapeutic areas: GastroenterologyImmunologyOncologyInfectious Diseases
Modalities: PeptidesSmall molecule
Industry: Biotech

Partnerships

Roche Venture Fund (investor, no direct pharma partnership found)

Beyond the preview

Go deeper on Inimex Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inimex Pharmaceuticals.

Explore the full profile